Efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in East Timor

American Journal of Tropical Medicine and Hygiene

Volumn 74, Issue 3, 2006, Pages 361-366

  Burns, Matthew ^b   Baker, Joanne ^a   Auliff, Alyson M ^a   Gatton, Michelle L ^c,d   Edstein, Michael D ^a   Cheng, Qin ^a  

^a AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FANSIDAR; ANTIMALARIAL AGENT; DIHYDROPTEROATE SYNTHASE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL DNA; PROTOZOAL PROTEIN; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GAMETOCYTE; GENE MUTATION; GENOTYPE; HUMAN; MALARIA; PARASITEMIA; PLASMODIUM FALCIPARUM; TIMOR-LESTE; ADOLESCENT; ADULT; AGED; ALLELE; ANIMAL; BLOOD; CHEMISTRY; CHILD; CLINICAL TRIAL; DRUG COMBINATION; ENZYMOLOGY; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; MALARIA FALCIPARUM; MALE; MIDDLE AGED; MUTATION; PARASITOLOGY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM;

ADOLESCENT; ADULT; AGED; ALLELES; ANIMALS; ANTIGENS, PROTOZOAN; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DIHYDROPTEROATE SYNTHASE; DNA, PROTOZOAN; DRUG COMBINATIONS; EAST TIMOR; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; MUTATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT OUTCOME;

EID: 33645971053     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2006.74.361     Document Type: Article

References (27)

1. Ezard N, Burns M, Lynch C, Cheng Q, Edstein MD, 2003. Efficacy of chloroquine in the treatment of uncomplicated Plasmodium falciparum infection in East Timor, 2000. Acta Trop 88: 87-90.
2. Chen N, Baker J, Ezard N, Burns M, Edstein MD, Cheng Q, 2002. Short report: Molecular evaluation of the efficacy of chloroquine treatment of uncomplicated Plasmodium falciparum malaria in East Timor. Am J Trop Med Hyg 67: 64-66.
3. White NJ, 1992. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 30: 571-585.
4. Nagesha HS, Din-Syafruddin, Casey GJ, Susanti AI, Fryauff DJ, Reeder JC, Cowman AF, 2001. Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in-vivo drug resistance in West Papua, Indonesia. Trans R Soc Trop Med Hyg 95: 43-49.
5. Walter RD, Konigk E, 1971. Plasmodium chabudi: enzymatic synthesis of dihydropteroate and its inhibition by sulfonamides. Z Trop Parasitol 22: 256-259.
6. Ferone R, Burchall JJ, Hitchings GH, 1969. Plasmodium berghei dihydrofolate reductase. Isolation, properties, and inhibition by antifolates. Mol Pharmacol 5: 49-59.
7. Triglia T, Menting JG, Wilson C, Cowman AF, 1997. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 94: 13944-13949.
8. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ, 1988. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A 85: 9109-9113.
9. Peterson DS, Walliker D, Wellems TE, 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A 85: 9114-9118.
10. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM, 2001. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 17: 582-588.
11. World Health Organization, 1996. Assessement of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated falciparum Malaria in Areas with Intense Transmission. Geneva: World Health Organization, 1-32. Available from http://wwwwhoint/drugresistance/en
12. World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated falciparum Malaria. Geneva: World Health Organization. WHO/HTM/RBM/2003 50, 1-67.
13. Ranford-Cartwright LC, Taylor J, Umasunthar T, Taylor LH, Babiker HA, Lell B, Schmidt-Ott JR, Lehman LG, Walliker D, Kremsner PG, 1997. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg 91: 719-724.
14. Duraisingh MT, Curtis J, Warhurst DC, 1998. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol 89: 1-8.
15. Edstein MD, Lika ID, Chongsuphajaisiddhi T, Sabchareon A, Webster HK, 1991. Quantitation of Fansimef components (mefloquine + sulfadoxine + pyrimethamine) in human plasma by two high-performance liquid chromatographic methods. Ther Drug Monit 13: 146-151.
16. Sowunmi A, Fateye BA, 2003. Changes in Plasmodium falciparum gametocytaemia in children with chloroquine-sensitive asexual infections. Parasite 10: 363-369.
17. von Seidlein L, Jawara M, Coleman R, Doherty T, Walraven G, Targett G, 2001. Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. Trop Med Int Health 6: 92-98.
18. Puta C, Manyando C, 1997. Enhanced gametocyte production in Fansidar-treated Plasmodium falciparum malaria patients: implications for malaria transmission control programmes. Trop Med Int Health 2: 227-229.
19. Robert V, Awono-Ambene HP, Le Hesran JY, Trape JF, 2000. Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. Am J Trop Med Hyg 62: 210-216.
20. Sutherland CJ, Alloueche A, Curtis J, Drakeley CJ, Ord R, Duraisingh M, Greenwood BM, Pinder M, Warhurst D, Targett GA, 2002. Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg 67: 578-585.
21. Snounou G, Beck HP, 1998. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 14: 462-467.
22. Basco LK, Ringwald P, 2000. Molecular epidemiology of malaria in Yaounde, Cameroon. VII. Analysis of recrudescence and reinfection in patients with uncomplicated falciparum malaria. Am J Trop Med Hyg 63: 215-221.
23. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, Dorsey G, 2003. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg 69: 247-252.
24. Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, Winstanley PA, Watkins WM, 1998. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother 42: 164-169.
25. Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF, 1996. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg 55: 209-213.
26. Nair S, Williams JT, Brockman A, Paiphun L, Mayxay M, Newton PN, Guthmann JP, Smithuis FM, Hien TT, White NJ, Nosten F, Anderson TJ, 2003. A selective sweep driven by pyrimethamine treatment in southeast Asian malaria parasites. Mol Biol Evol 20: 1526-1536.
27. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T, 2004. Intercontinental spread of pyrimethamine-resistant malaria. Science 305: 1124-1124.